Molecular Profile Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Profile Name ERBB3 positive
Gene Variant Detail

ERBB3 positive (unknown)

Relevant Treatment Approaches

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
ERBB3 positive melanoma sensitive Canertinib Preclinical Actionable In a preclinical study, ERBB3 (HER3)-positive melanoma cells were sensitive to Canertinib, resulting in decreased metastasis in mouse models (PMID: 25000258). 25000258
ERBB3 positive Advanced Solid Tumor sensitive Lumretuzumab Phase I Actionable In a Phase I trial, Lumretuzumab treatment resulted in stable disease in 21.3% (10/47) of patients with Erbb3 (Her3)-expressing advanced solid tumors (PMID: 26463709). 26463709
ERBB3 positive triple-receptor negative breast cancer sensitive Lumretuzumab Phase I Actionable In a Phase I trial, Lumretuzumab treatment resulted in tumor shrinkage in a patient with Erbb3 (Her3)-expressing triple-receptor negative breast cancer (PMID: 26463709). 26463709
ERBB3 positive melanoma sensitive CDX-3379 Preclinical Actionable In a preclinical study, CDX-3379 (KTN3379) inhibited proliferation and ERBB3 (HER3)-AKT signaling in a human melanoma cell line with autocrine ERBB3 (HER3) signaling in culture (PMID: 26880266). 26880266
ERBB3 positive breast cancer sensitive CDX-3379 Preclinical Actionable In a preclinical study, CDX-3379 (KTN3379) inhibited proliferation of a human breast cancer cell line with autocrine ERBB3 (HER3) signaling in culture (PMID: 26880266). 26880266
ERBB3 positive head and neck squamous cell carcinoma predicted - sensitive CDX-3379 Phase I Actionable In a Phase I trial, CDX-3379 (KTN3379) treatment decreased tumor Erbb3 phosphorylation levels in 83% (10/12) of patients with head and neck squamous cell carcinoma, with 50% or more reduction in 58% (7/12) of patients, and 42% (5/12) patients achieved shrinkage of tumor burden (PMID: 31308059; NCT02473731). 31308059
ERBB3 positive colorectal cancer sensitive Patritumab deruxtecan Preclinical - Cell line xenograft Actionable In a preclinical study, Patritumab Deruxtecan (U3-1402) decreased viability of Erbb3 (Her3)-positive colorectal cancer cell lines in culture and induced significant tumor growth inhibition in cell line xenograft models with intermediate to high Erbb3 (Her3) expression (PMID: 31395690). 31395690
ERBB3 positive colorectal cancer predicted - sensitive Patritumab Preclinical - Cell line xenograft Actionable In a preclinical study, Patritumab treatment resulted in reduced Erbb3 (Her3) phosphorylation in Erbb3 (Her3)-positive colorectal cancer cell lines in culture and modest antitumor activity in cell line xenograft models (PMID: 31395690). 31395690
ERBB3 positive colon cancer sensitive ISU104 Preclinical - Cell line xenograft Actionable In a preclinical study, ISU104 treatment inhibited Erbb3 phosphorylation and downstream signaling in a colon cancer cell line in culture, and inhibited tumor growth in a cell line xenograft model (PMID: 33782100). 33782100
ERBB3 positive head and neck squamous cell carcinoma sensitive ISU104 Preclinical - Cell line xenograft Actionable In a preclinical study, ISU104 treatment inhibited Erbb3 phosphorylation and downstream signaling in head and neck squamous carcinoma cell lines in culture, and resulted in tumor regression in cell line xenograft models (PMID: 33782100). 33782100
ERBB3 positive pancreatic cancer sensitive ISU104 Preclinical - Cell line xenograft Actionable In a preclinical study, ISU104 treatment inhibited Erbb3 phosphorylation, downstream signaling, and proliferation of pancreatic cancer cells in culture, and inhibited tumor growth in a cell line xenograft model (PMID: 33782100). 33782100
ERBB3 positive breast cancer sensitive ISU104 Preclinical - Cell line xenograft Actionable In a preclinical study, ISU104 treatment inhibited Erbb3 phosphorylation, downstream signaling, and proliferation in breast cancer cell lines in culture, and inhibited tumor growth in cell line xenograft models (PMID: 33782100). 33782100
ERBB3 positive lung non-small cell carcinoma sensitive ISU104 Preclinical - Cell line xenograft Actionable In a preclinical study, ISU104 treatment inhibited Erbb3 phosphorylation and downstream signaling in a non-small cell lung cancer cell line in culture, and inhibited tumor growth in a cell line xenograft model (PMID: 33782100). 33782100
ERBB3 positive skin cancer sensitive ISU104 Preclinical - Cell line xenograft Actionable In a preclinical study, ISU104 treatment inhibited Erbb3 phosphorylation and downstream signaling in a skin cancer cell line in culture, and inhibited tumor growth in a cell line xenograft model (PMID: 33782100). 33782100
ERBB3 positive Her2-receptor negative breast cancer predicted - sensitive Patritumab deruxtecan Phase Ib/II Actionable In a Phase I/II trial (U31402-A-J101), Patritumab deruxtecan (U3-1402) therapy demonstrated safety and efficacy in previously treated metastatic hormone receptor-positive, ERBB2 (HER2)-negative breast cancer patients expressing ERBB3 (HER3) (n=113), with an objective response rate of 30.1%, disease control rate of 80.5%, with partial response in 30.1% and stable disease in 50.4% of patients, median progression-free survival of 7.4 mo, and median overall survival of 14.6 mo (PMID: 37801674; NCT02980341). 37801674
ERBB3 positive breast cancer predicted - sensitive DB-1310 Preclinical - Cell line xenograft Actionable In a preclinical study, DB-1310 inhibited tumor growth in an ERBB3 (HER3)-positive breast cancer cell line xenograft model (PMID: 38632563). 38632563
ERBB3 positive Her2-receptor negative breast cancer predicted - sensitive Patritumab deruxtecan Clinical Study Actionable In a clinical study, Patritumab deruxtecan (U3-1402) treatment demonstrated efficacy in patients with ERBB3 (HER3)-positive, ERBB2 (HER2)-negative breast cancer, resulting in increased immune infiltration as measured by a median increase of 3.5 in the CelTIL score, and an overall response rate of 45.2% (28/62, 14 complete and 14 partial responses) (PMID: 37211044; NCT04610528). 37211044
ERBB3 positive Her2-receptor negative breast cancer predicted - sensitive Patritumab deruxtecan Phase II Actionable In a Phase II trial, Patritumab deruxtecan (U3-1402) treatment resulted in an objective response rate (ORR) of 35%, clinical benefit rate (CBR) of 48%, median duration of response of 10 mo, and 6-mo progression-free survival (PFS) rate of 60% in ERBB3 (HER3)-positive, ERBB2 (HER2)-negative metastatic breast cancer patients, with an ORR of 46 vs 33%, CBR of 54 vs 50%, and PFS rate of 70 vs 50% in those with 25-75% vs >/=75% ERBB3 (HER3) expression (J Clin Oncol 41, 2023 (suppl 16; abstr 1004); NCT04699630). detail...
ERBB3 positive lung non-small cell carcinoma sensitive AMT-562 Preclinical - Cell line xenograft Actionable In a preclinical study, AMT-562 inhibited tumor growth in a cell line xenograft model of ERBB3 (HER3)-positive non-small cell lung cancer (PMID: 37302522). 37302522
ERBB3 positive colon cancer sensitive AMT-562 Preclinical - Cell line xenograft Actionable In a preclinical study, AMT-562 inhibited tumor growth in a cell line xenograft model of ERBB3 (HER3)-positive colon cancer with a complete response in 4 of 5 mice and inhibited growth in patient-derived organoids in culture (PMID: 37302522). 37302522
ERBB3 positive breast cancer predicted - sensitive AMT-562 Preclinical - Cell line xenograft Actionable In a preclinical study, AMT-562 inhibited tumor growth in a cell line xenograft model of low ERBB3 (HER3)-expressing breast cancer (PMID: 37302522). 37302522
ERBB3 positive esophagus adenocarcinoma sensitive AMT-562 Preclinical - Pdx Actionable In a preclinical study, AMT-562 inhibited tumor growth in a patient-derived xenograft (PDX) model of ERBB3 (HER3)-positive esophageal adenocarcinoma (PMID: 37302522). 37302522
ERBB3 positive esophagus squamous cell carcinoma sensitive AMT-562 Preclinical - Pdx Actionable In a preclinical study, AMT-562 inhibited tumor growth in a patient-derived xenograft (PDX) model of ERBB3 (HER3)-positive esophageal squamous cell carcinoma (PMID: 37302522). 37302522
ERBB3 positive gastroesophageal junction adenocarcinoma sensitive AMT-562 Preclinical - Pdx Actionable In a preclinical study, AMT-562 inhibited tumor growth in a patient-derived xenograft (PDX) model of ERBB3 (HER3)-positive gastroesophageal junction adenocarcinoma (PMID: 37302522). 37302522
ERBB3 positive stomach cancer sensitive AMT-562 Preclinical - Cell line xenograft Actionable In a preclinical study, AMT-562 inhibited tumor growth in a cell line xenograft model of ERBB3 (HER3)-positive gastric cancer (PMID: 37302522). 37302522
ERBB3 positive lung non-small cell carcinoma sensitive DB-1310 Preclinical - Pdx Actionable In a preclinical study, DB-1310 inhibited tumor growth in ERBB3 (HER3)-positive non-small cell lung cancer cell line xenograft and patient-derived xenograft (PDX) models (PMID: 38632563). 38632563
ERBB3 positive colon cancer sensitive DB-1310 Preclinical - Cell line xenograft Actionable In a preclinical study, DB-1310 inhibited tumor growth in an ERBB3 (HER3)-positive colon cancer cell line xenograft model (PMID: 38632563). 38632563
ERBB3 positive prostate cancer sensitive DB-1310 Preclinical - Pdx Actionable In a preclinical study, DB-1310 inhibited tumor growth in ERBB3 (HER3)-positive prostate cancer patient-derived xenograft (PDX) models (PMID: 38632563). 38632563